InsiderSignal.AI

InsiderSignal.ai

LEXX - Lexaria Bioscience Corp.

Insider Purchase by Bunka Christopher (Dir)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Bunka Christopher, serving as Dir at Lexaria Bioscience Corp. (LEXX), purchased 27,500 shares at $0.92 per share, for a total transaction value of $25,241.00. Following this transaction, Bunka Christopher now holds 909,867 shares of LEXX.

This purchase represents a 3.00% increase in Bunka Christopher's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, July 29, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, July 30, 2025, 1 day after the trade was made.

Lexaria Bioscience Corp. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Bunka Christopher

Dir

Chris Bunka (also referred to as Bunka Christopher) is a seasoned serial entrepreneur with over three decades of experience in capital markets, project acquisition, corporate finance, and corporate governance.[[1]](https://www.investorbrandnetwork.com/executive-profiles/chris-bunka-chairman-and-ceo-lexaria-bioscience-corp/)[[3]](https://www.moneyshow.com/expert/d98b5d20369d466cbac1323ea25da925/) He has been a key figure at Lexaria Bioscience Corp. (NASDAQ: LEXX) since 2006, serving as Chairman of the Board and CEO until August 31, 2024, when he transitioned to Chairman of the Board and Executive Strategic Advisor.[[2]](https://lexariabioscience.com/2024/09/05/lexaria-welcomes-industry-veteran-as-new-ceo/)[[5]](https://lexariabioscience.com/investors/board-of-directors/)[[6]](https://lexariabioscience.com/investors/management-team/) Bunka is a named inventor on several of Lexaria's patents related to its DehydraTECH drug delivery platform and is a published author and public speaker on investment strategies.[[1]](https://www.investorbrandnetwork.com/executive-profiles/chris-bunka-chairman-and-ceo-lexaria-bioscience-corp/)[[3]](https://www.moneyshow.com/expert/d98b5d20369d466cbac1323ea25da925/) Under Bunka's leadership, Lexaria advanced its DehydraTECH technology, focusing on improved oral drug delivery for cardio-metabolic drugs, including GLP-1 formulations for weight loss and hypertension.[[2]](https://lexariabioscience.com/2024/09/05/lexaria-welcomes-industry-veteran-as-new-ceo/) His contributions have positioned the company for pharmaceutical collaborations, including a recent Material Transfer Agreement.[[2]](https://lexariabioscience.com/2024/09/05/lexaria-welcomes-industry-veteran-as-new-ceo/) As a director and recent trader in LEXX stock, Bunka continues to provide strategic guidance to the management team.[[2]](https://lexariabioscience.com/2024/09/05/lexaria-welcomes-industry-veteran-as-new-ceo/)[[5]](https://lexariabioscience.com/investors/board-of-directors/)

View full insider profile →

Trade Price

$0.92

Quantity

27,500

Total Value

$25,241.00

Shares Owned

909,867

Trade Date

Tuesday, July 29, 2025

208 days ago

SEC Filing Date

Wednesday, July 30, 2025

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Lexaria Bioscience Corp.

Company Overview

No company information available
View news mentioning LEXX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/92121

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime